The anti-myeloma effect of BI836909 was not significantly affected by the presence of bone marrow stromal cells, soluble BCMA and APRIL (up to 150 and 100 ng/ml, respectively). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.